A roundtable discussion, moderated by Michael Morris, MD, discussed the current landscape of radioligand therapy in prostate cancer, including recent trial highlights presented at ESMO 2023. Dr. Morris was joined by Tanya Dorff, MD; Evan Yu, MD; and Rana McKay, MD. In the final segment of the roundtable series, the panel shares insights on future advancements in the field, including PSMA-directed Actinium studies and radioligand combination therapy. ...
Advanced Imaging
Advertisement
Latest News
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
The panel talks "pearls of wisdom" with radioligand therapy.
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Advertisement
